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Objective: A consistent pathologic feature seen in lungs of patients with pulmonary
hypertension from thromboembolic disease is hyperplasia of the media of pul-
monary arterioles. The molecular factors responsible for these vessel wall changes
are unknown. Angiopoietin-1 is a gene responsible for the formation of the media
of blood vessels in utero. We hypothesized that aberrant expression of the angiopoi-
etin-1 gene in the adult lung would be a major contributing factor in the develop-
ment of pulmonary hypertension.
Methods: From April 1999 to March 2000, a total of 35 patients (18 men, 17
women, mean age 52 years) with pulmonary hypertension and pulmonary vas-
cular resistance ranging from 407 to 2006 dynes · sec · cm–5 underwent pul-
monary endarterectomy at our institution. Before cardiopulmonary bypass, lung
biopsy specimens were taken from each patient. Biopsy specimens were also
obtained from 10 patients (5 women, 5 men, mean age 55 years) undergoing lung
resection for causes other than pulmonary hypertension. All specimens were
blindly scored by a pathologist for degree of medial hyperplasia. Quantitative
reverse transcriptase–polymerase chain reaction, Western blot, and immunohis-
tochemistry were used to quantitate angiopoietin-1 messenger RNA and protein
in each sample.
Results: Lung specimens from all patients with pulmonary hypertension demon-
strated up-regulation of angiopoietin-1 at the messenger RNA level. The degree of
angiopoietin-1 transcription was directly proportional to the preoperative pul-
monary vascular resistance and medial wall hyperplasia/hypertrophy in each
patient. By immunohistochemistry, angiopoietin-1 protein was confined to the
media of pulmonary arterioles. Lung biopsy specimens from patients without pul-
monary hypertension had no detectable expression of angiopoietin-1 at the messen-
ger RNA or protein level.
Conclusion: Angiopoietin-1, a gene responsible for vessel development in the
embryonic lung, is up-regulated in the lung parenchyma of patients with pul-
monary hypertension. The level of expression of angiopoietin-1 at messenger
RNA and protein levels correlates to the severity of pulmonary hypertension in
patients with thromboembolic disease and serves as a target for strategies to treat
this disease. 
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One of the major pathologic features ofchronic pulmonary hypertension is mus-cular hypertrophy and hyperplasia ofsmall pulmonary arterioles and capillaries.This process is progressive, diffuse, andeventually results in obliteration of the
distal pulmonary arterial tree. Muscularization of small pul-
monary vessels occurs in all forms of pulmonary hyperten-
sion, including primary idiopathic disease as well as that
induced by thromboembolism, drugs, or pulmonary shunt.1
Although this pathologic condition is seen in both adults
and children with pulmonary hypertension, the mechanism
of this vasculopathy is unknown.
Pulmonary hypertension develops in patients with signifi-
cant chronic thromboembolic disease of the lung.2 At the
microscopic level, the pulmonary vasculature of these
patients reveals two distinct pathologic processes. The prox-
imal pulmonary artery tree contains focal macroscopic orga-
nized thrombus and pronounced intimal thickening, and the
distal pulmonary tree contains small-vessel muscular hyper-
trophy and hyperplasia.3 Complete surgical removal of the
proximal thrombus and intimal thickening in the proximal
pulmonary arterial tree by endarterectomy achieves normal-
ization of pulmonary arterial pressures and arrests the distal
small-vessel vasculopathy.4
Establishment and muscular remodeling of blood vessels
is regulated by paracrine signals between endothelial and
smooth muscle cells.5 Angiopoietin-1 (Ang-1), a 70-kd
secreted peptide, is an angiogenic factor essential for nor-
mal lung vascular development. Produced by smooth mus-
cle cells and smooth muscle cell precursor pericytes, Ang-1
functions to stabilize blood vessel development by recruit-
ing muscle cells, through migration and division, to nascent
endothelial tubes, creating mature arterial structures.6
Animals deficient in Ang-1 by null mutation die in utero
with little arterial development in the lung and other
organs.7 The two receptors for Ang-1, TIE1 and TIE2, are
present only on vascular endothelium. The ligand-receptor
interaction between smooth muscle cell–secreted Ang-1 and
the endothelium-specific TIE receptors in organ develop-
ment induces proliferation of smooth muscle cells around
the growing endothelial vascular network.8 After pulmonary
development and maturation are completed, Ang-1 is not
expressed in the human lung.
Since pulmonary hypertension is a disease of excessive
muscular investment of pulmonary capillaries and arterioles,
we hypothesized that this process may be due to aberrant
expression of Ang-1 gene product. To evaluate the role of
Ang-1 in pulmonary hypertension, we examined lung tissue
from patients with this disease undergoing pulmonary
endarterectomy at our institution for deregulation of Ang-1
gene and protein expression.
Methods
Patient Selection
Between April 1999 and March 2000, 45 patients (22 men and 23
women; mean age 53.5 years; range 27-73 years) undergoing
either pulmonary endarterectomy or pulmonary resection were
enrolled in this study. Thirty-five of the patients underwent pul-
monary endarterectomy for end-stage pulmonary hypertension
(mean pulmonary vascular resistance [PVR] 717 dynes · sec ·
cm–5; range 407-2006 dynes · sec · cm–5). Ten control patients
with normal PVR underwent wedge resection of the lung for
benign pulmonary nodules (mean PVR 177.5 dynes · sec · cm–5;
range 145-210 dynes · sec · cm–5). According to the usual prac-
tice at our institution, pulmonary hypertension was defined as
PVR greater than 300 dynes · sec · cm–5 and pulmonary artery
systolic pressure greater than 50 mm Hg.9
The selection criteria for patients undergoing pulmonary
endarterectomy included the following: (1) New York Heart
Association class III or IV, (2) PVR greater than 300 dynes · sec ·
cm–5, (3) absence of significant comorbid disease unrelated to
right-sided heart failure, and (4) the appearance of chronic throm-
bi on angiography.10 All patients enrolled in this study were
between 35 and 80 years of age and had given written informed
consent for lung biopsy. The study was approved by the University
of California, San Diego, Institutional Review Board.
Biopsy of Lung
After induction of anesthesia and either median sternotomy (for
pulmonary endarterectomy) or thoracotomy (for lung resection),
the lung of each patient was examined and a 4-cm biopsy specimen
was taken with the use of a GIA tissue stapler (United States
Surgical Corporation, Auto Suture Company Division, Norwalk,
Conn). For patients undergoing pulmonary endarterectomy, the
biopsy tissue was taken from a segment of lung most involved with
pulmonary occlusive disease according to preoperative angiogra-
phy. Specimens were taken before cardiopulmonary bypass and
during ventilation with an inspired oxygen fraction (FIO2) of 100%
and peripheral oxygen saturations of greater than 95%. Specimens
from patients with benign lung nodules were taken before anatom-
ic resection and during ventilation with an FIO2 of 100% and
peripheral oxygen saturations of greater than 95%.
Sample Preparation and Extraction of RNA and
Protein
One third of each biopsy specimen was fixed in formalin, sec-
tioned to a thickness of 5 µm, mounted on a slide, and stained with
hematoxylin and eosin. The mounted specimens were examined by
light microscopy to quantitate the pathologic severity of pul-
monary hypertension in each sample. The remaining lung speci-
mens were frozen in liquid nitrogen at –140°C and later processed
for RNA and protein extraction.
For total RNA isolation, portions of the frozen samples were
lyophilized, and then RNA was extracted by means of the acid
guanidinium thiocyanate-phenol-chloroform technique, as previ-
ously described.11,12 The recovered RNA pellet was dried under
vacuum conditions for 10 minutes and then dissolved in diethyl
pyrocarbonate–treated deionized distilled water. The concentration
Surgery for Acquired Cardiovascular Disease Thistlethwaite et al
Thistlethwaite et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 1 67
TX
ET
CS
P
A
CD
CH
D
A
CD
ED
IT
O
RI
A
L
and purity of the RNA were determined by spectrophotometric
analysis (Ultro-spec II, Biochrom, Cambridge, United Kingdom)
at 260 and 280 nm. The samples were stored at –80°C until ana-
lyzed.
For protein isolation, portions of the frozen lung samples were
prepared for protein purification as previously described.13
Portions of each recovered protein extract were tested in a
Bradford Protein Assay (Bio-Rad Microscience, Hercules, Calif)
to determine total protein concentration of each sample. Protein
extracts were used fresh or stored at –80°C until used.14
Measurement of Ang-1 Messenger RNA (mRNA)
The reverse-transcriptase polymerase chain reaction (RT-PCR) was
used to analyze each lung specimen for the presence of transcripts
encoding Ang-1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). GAPDH mRNA was studied as a marker to control for
variation in RNA concentration and RNA degradation as potential
confounding variables. Total RNA (5 µg) was used to synthesize
complementary DNA (cDNA) with SuperScript II Reverse
Transcriptase and oligo (dT)12-18 (Gibco BRL, Life Technologies,
Inc, Rockville, Md). The synthesized primers had the following
sequences: for Ang-1, 5´ GGCAACTGTCGTGAGAGTACGA 3´
and 5´ ATTTAGATTGGAGGGGCCACA 3´ (Gibco BRL); for
GAPDH, 5´ CATCATCTCTGCCCCCTC TG 3´ and 5´ CCT-
GCTTCACCACCTTCTTG 3´ (Genbase Inc, San Diego, Calif).
Duplicate amplification reactions were carried out with a single
block thermocycler (Ericomp Inc, San Diego, Calif) containing 0.2
µmol/L of each primer, deoxynucleotide triphosphates (200
mmol/L each), 1.5 mmol/L magnesium chloride, 0.5 unit of Taq
DNA polymerase, and 36.5 µL of autoclaved distilled water. Each
sample underwent initial denaturation at 94°C for 5 minutes, 38
cycles of denaturation at 94°C for 1 minute, annealing at 62°C for
2 minutes, extension at 72°C for 2 minutes, and a final extension
at 72°C for 10 minutes. The PCR products were electrophoresed
on a 1% agarose gel containing 0.2 µg/mL ethidium bromide in
Tris–acetate–ethylenediaminetetraacetic acid buffer. The gels were
photographed with a digital electrophoresis photodocumentation
camera (Fisher Scientific, Pittsburgh, Pa).
Quantitative comparative PCR methods were used to quantitate
steady-state levels of Ang-1 transcripts.15 PCR amplifications for
Ang-1 and GAPDH were performed on lung specimens that
demonstrated Ang-1 transcripts on nonquantitative PCR analysis.
Ang-1 and GAPDH were synthesized in the conditions described
above, but were removed at specific cycle numbers of 16, 20, 24,
28, 32, 36, and 40. These products were electrophoresed on 1%
agarose gels. The resulting bands were digitally photographed and
quantitated for density using the IS-1000 digital imaging system
(Alpha Innotech Corporation, San Leandro, Calif). For each sam-
ple amplification series, the densities in pixels were digitally plot-
ted versus cycle number. By this method the linear and plateau
phases were noted to be at 24 and 32 cycles, respectively. For each
sample, the densities of Ang-1 products were compared with the
densities of GAPDH products, with GAPDH serving as an internal
standard control. The ratio of Ang-1 product to GAPDH product at
cycle 24 (linear phase) was obtained by dividing Ang-1 band den-
sity by GAPDH band density.
Measurement of Ang-1 Protein
Western blot analysis was performed with the use of a previously
described protocol.16 In brief, 10 µg of each protein extract was
diluted with an equal volume of 2× SDS sample buffer (Novex,
San Diego, Calif). Samples were loaded into a 4% to 20% TG-gel
(Novex) in equal protein concentrations and electrophoresed at 60
to 100 volts for 5 hours. The gel products were transferred at 22
volts for 12 hours at 4°C to a nitrocellulose membrane using the
Novex-Cell II apparatus (Novex). The nitrocellulose was incubat-
ed in washing buffer (10 mmol/L Tris-HCl at pH 8.0, 150 mmol/L
NaCl, 0.2% gelatin, 0.05% Tween-20, 0.2% bovine serum albu-
min). Blocking was performed by means of 3% bovine serum albu-
min washing buffer for 1 hour at room temperature. The nitrocel-
lulose was then cleaned with washing buffer for 5 minutes.
Subsequently, the primary antibody, goat polyclonal
immunoglobulin G (IgG) anti-human Ang-1 (Santa Cruz
Biotechnology, Santa Cruz, Calif) at 1:500 dilution in 3% bovine
serum albumin washing buffer, was added for overnight binding at
4°C. The nitrocellulose was then incubated in washing buffer for 3
cycles of 5 minutes each. The secondary antibody, anti-goat IgG
alkaline phosphatase (Santa Cruz Biotechnology), diluted 1:1000,
was incubated with the nitrocellulose membrane for 1 hour at room
temperature. The membrane was then bathed in washing buffer for
3 cycles of 5 minutes each, then placed into substrate solution (100
mmol/L Tris-HCl, 100 mmol/L NaCl, 5 mmol/L MgCl2 at pH 9.5,
165 µg/mL 5-bromo-4 chloro-3-indolyl-phosphate, 330 µg/mL
nitro blue tetrazolium) until protein bands were visible. The filters
were then placed in distilled water, dried, and imaged using a dig-
ital scanner (Hewlett-Packard ScanJet, Palo Alto, Calif).
The same procedure was performed for actin, which acted as an
internal control, using mouse anti-human actin IgG primary mouse
monoclonal antibody (Santa Cruz Biotechnology) at 1:3000 dilu-
tion and goat anti-mouse IgG (H+L) alkaline phosphatase
(Southern Biotechnology Associates, Birmingham, Ala) at 1:1000
dilution.
Immunohistochemical Staining for Ang-1 
Portions of the frozen biopsy specimens were fixed in 10% forma-
lin and prepared as 5-µm thick tissue sections on slides. The paraf-
fin was then removed with a xylene substitute (Hemo-De; Fisher
Scientific, Pittsburgh, Pa) and the sections were rehydrated with
ethanol gradient washes. The sections were incubated with goat
anti-human Ang-1 polyclonal IgG (Santa Cruz Biotechnology) at a
1:100 dilution. Control sections were incubated with diluted nor-
mal goat serum (Vector Laboratories, Burlingame, Calif) in lieu of
primary antibody. All sections were subsequently incubated with
biotinylated secondary anti-goat antibodies and stained with an
immunoperoxidase technique (Vectastain Elite ABC reagents,
Vector Laboratories). Sections were dried and mounted (Gel
Mount; Biomeda Corp, Foster City, Calif), examined with a pho-
tomicroscope, and photographed on color film (Fujicolor 100; Fuji
Photo Film Co, Tokyo, Japan).
Statistical Analysis
The 35 patients undergoing pulmonary endarterectomy and 10
control patients were compared according to preoperative medical
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variables by means of a Student independent group t test for nor-
mally distributed variables and Wilcoxon rank sum test for those
measures that were not normal. Gender between the pulmonary
endarterectomy and control cohorts was compared by means of a
Fisher exact test. Group mean and standard deviation or median
(range) are reported for each normal and non-normal variable,
respectively. Sex for each group is shown as sample size (propor-
tion male).
Results
All lung biopsy specimens were examined by light
microscopy to quantitate pulmonary hypertensive changes
according to the Heath-Edwards classification17 by a lung
pathologist who was unaware of the patient’s identity. Each
of the 35 specimens taken from patients undergoing pul-
monary endarterectomy demonstrated Heath-Edwards stage
2 to 5 disease with diffuse medial arteriolar hypertrophy/
hyperplasia and stenosis of at least one third of all viewed
capillaries/arterioles. The 10 specimens taken from patients
without pulmonary hypertension demonstrated normal lung
histologic characteristics or scattered bullous emphysema.
A direct correlation existed between preoperative clinical
variables (pulmonary artery pressures, PVR) and the patho-
logic classification of each affected specimen. Figure 1
shows representative biopsy abnormalities from the 2
groups of patients.
The characteristics, cardiac indices, and pulmonary func-
tion measurements of the patients before operation and lung
biopsy are shown in Table 1. The pulmonary endarterecto-
my patients and controls were similar with respect to age,
sex, arterial oxygen tension, FIO2, pulmonary capillary
wedge pressure, cardiac output, single-breath diffusing
capacity for carbon monoxide, forced expiratory volume in
Surgery for Acquired Cardiovascular Disease Thistlethwaite et al
Figure 1. Pathologic changes in representative lung biopsy
specimens (hematoxylin and eosin stain, × 400). Normal pul-
monary arteriolar structure is seen in a patient without pul-
monary hypertension (A), medial arteriolar hyperplasia/ hyper-
trophy in a patient with a PVR of 655 dynes · sec · cm–5 (B), and
obliteration of pulmonary arteriolar lumen by smooth muscle
cell deposition in a patient with a PVR of 1541 dynes · sec · cm–5
(C).
Figure 2. Results of analysis of lung biopsy tissue by the PCR. Lung
specimens 1 to 7 were taken from patients with a PVR greater than
500 dynes · sec · cm–5. Lung specimens A to C were taken from
patients with a PVR less than 210 dynes · sec · cm–5. Transcript
lengths detected are shown on the right. PTE, Pulmonary throm-
boendarterectomy; bp, base pair.
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1 second, and hematocrit. The pulmonary endarterectomy
group had significantly higher pulmonary artery systolic
and diastolic pressures and PVR compared to the control
group (P < .0001). No inferential statistical comparison was
made for FIO2 because an FIO2 of 100% was used in all sub-jects in both groups at the time of biopsy.
Molecular Analysis of Lung Specimens
Figure 2 shows the results of nonquantitative PCR analy-
sis of samples of RNA from lung specimens from the 2
groups of patients. The 35 patients with pulmonary hyper-
tension undergoing pulmonary endarterectomy had
detectable steady-state levels of Ang-1 mRNA in their
lung biopsy tissue. Ang-1 transcripts were not detected in
any biopsy specimens from patients with a PVR less than
300 dynes · sec · cm–5. The Ang-1 mRNA detected in all
the affected specimens was 1200 base pairs long. This
Ang-1 transcript corresponds to the known 70-kd Ang-1
protein. We found that levels of GAPDH mRNA were
consistently equal among the samples studied.
Patients with a higher preoperative PVR had greater
amounts of steady-state Ang-1 mRNA in the lung as
assayed by semiquantitative PCR analysis. Indeed, the
degree of Ang-1 gene expression correlated directly with the
severity of pulmonary hypertension as measured by the pre-
operative PVR and pulmonary artery pressure. Figure 3
shows the results of semiquantitative PCR using mRNA
from 3 patients with varying severities of pulmonary hyper-
tension. GAPDH served as an internal control to establish
relative band density ratios in these patients. We found this
direct correlation between gene expression and phenotype
(elevated PVR) in all patient samples studied. Ang-1 mRNA
was not detected by quantitative PCR analysis in the periph-
eral blood or main pulmonary artery wall of patients (data
not shown), suggesting this protein and its effect are con-
fined to the lung.
Quantitation and Localization of Ang-1 Protein in
Pulmonary Endarterectomy Lung Specimens
By Western blot analysis, Ang-1 protein was detected in the
lungs of all patients with pulmonary hypertension and was
not present in biopsy specimens of patients undergoing lung
resection for benign causes (Figure 4). The Ang-1 protein
was detected as a 70-kd peptide, corresponding to the known
weight of this moiety in human beings. Patients with a high-
er preoperative PVR had increased levels of Ang-1 protein in
their lung biopsy specimens as compared with lung tissue
taken from patients with a normal PVR. The magnitude of
Ang-1 protein present for a given lung specimen directly cor-
related with the severity of the preoperative PVR (Figure 5),
as well as the degree of pulmonary hypertensive changes
identified by pathologic analysis. Actin protein was con-
comitantly measured in each protein sample to ensure
against confounding variables such as protein degradation or
variation in protein concentration. Actin protein was consis-
tently equal in amount among all samples studied.
Immunohistochemical staining with antibody to Ang-1 of
sectioned biopsy specimens from patients with elevated PVR
revealed that Ang-1 protein was confined to the media of pul-
monary arterioles and small muscular arteries measuring less
than 500 µm in size (Figure 6). Immunoreactivity was identi-
fied in the cytoplasm of smooth muscle cells lining these small
TABLE 1. Preoperative clinical variables*
PTE patients Controls P value
Total patients 35 10
Male 17 (49%) 5 (50%) 1.00
Age (y) 52 ± 30.5 55 ± 25.7 .36
PaO2 (mm Hg) 296.7 ± 110.8 270.5 ± 63.5 .48
FIO2 (%) 100 ± 0 100 ± 0 —
PA systolic (mm Hg) 83.2 ± 16.3 30.7 ± 9.1 .0001
PA diastolic (mm Hg) 36.3 ± 9.4 13.0 ± 7.0 .0001
PVR (dynes · sec · cm–5)† 717.0 (407, 2006) 177.5 (145, 210) .0001
PCW (mm Hg)† 10.0 (6, 15) 9 (5, 14) .53
CO (L/min) 3.27 ± 0.8 3.6 ± 0.8 .31
FEV1 (% predicted) 69 ± 11.8 66 ± 14.1 .68
DLCO 71.4 ± 16.2 67.7 ± 16.7 .53
Hematocrit 38.5 ± 4.1 38.8 ± 3.2 .84
PaO2, Partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen; PA, pulmonary artery; PVR, pulmonary vascular resistance; PCP, pulmonary cap-
illary wedge pressure; CO, cardiac output; FEV1, forced expiratory volume in 1 second; DLCO, single breath diffusion of carbon monoxide.
*Values are means ± standard deviation or number (%).
†Median (range).
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lung vessels (Figure 7). Ang-1 protein was not detected in
alveolar parenchyma, large pulmonary arteries, or pulmonary
veins. Ang-1 protein was not detected by immunohistochemi-
cal staining in the lungs of patients with normal PVR.
Discussion
The genesis of pulmonary hypertension is a complex vascu-
lar process involving alterations in vessel wall anatomy in
the lung. In the early phases of pulmonary hypertension, the
distal pulmonary vasculature is morphologically normal but
capable of exaggerated vasoconstriction.18 As the disease
progresses, clear-cut morphologic changes in the distal pul-
monary arterioles occur, resulting in muscular hyperplasia
and hypertrophy of the medial layer of these vessels.19 This
vessel wall thickening obstructs arteriolar blood flow and
eventually results in obliteration of the distal pulmonary
arterial tree.20 Although mechanisms of increased pul-
monary blood flow, hypoxia, and increased pulmonary arte-
rial bed pressures have been speculated to be triggers of this
vasculopathy, little is known about the molecular signals
that generate this process. Administration of epoprostenol
(prostacyclin) analogs or nitric oxide to patients with pul-
monary hypertension is known to attenuate the vasoreactive
component of the disease but has made little impact in
arresting the resultant pulmonary arteriolar hyperplasia and
hypertrophy, which ultimately destroy the lung and lead to
right-sided heart failure.21,22
One of the more common causes of pulmonary hyperten-
sion in adults is chronic thromboembolism to the lung. In
selected patients, pulmonary endarterectomy is an effective
modality for treating proximal thromboembolic disease in
the pulmonary artery tree.23 Our institution performs more
than 100 pulmonary endarterectomies a year for throm-
boembolic pulmonary hypertension.24 This patient popula-
tion represents a major resource for the clinical and basic
science study of this disease. Pulmonary endarterectomy
treats two disease processes in the lung. First, by direct sur-
gical manipulation, organized thrombus and fibrotic thick-
ening in the intima of the first few divisions of the pul-
monary tree are removed. Second, this equalization of blood
flow throughout the lung arrests the progression of distal
arteriolar vasculopathy. By pathologic analysis, we have
found that the small-vessel medial hyperplastic and hyper-
trophic response occurs throughout the lung, irrespective to
the lobar or segmental artery affected by the thromboem-
bolic disease.
Surgery for Acquired Cardiovascular Disease Thistlethwaite et al
Figure 3. Quantitative comparative RT-PCR of Ang-1 mRNA in 3
patients with ranging degrees of PVR. Ratio reflects Ang-1 band
density divided by standard GAPDH band density at linear cycle 24.
Figure 4. Western blot quantitation of Ang-1 protein. The molecu-
lar weights of Ang-1 and actin proteins detected are shown on the
right in kilodaltons (kD). PTE, Pulmonary thromboendarterectomy.
Figure 5. Linear regression analysis demonstrating correlation
between Ang-1 protein expression in the lung to degree of preop-
erative PVR in 45 patients. The Y axis denotes Western blot band
densities of Ang-1 normalized to actin. The X axis denotes PVR
(dynes · sec · cm–5). 
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The goal of this study was to examine specimens of
human lung tissue affected by thromboembolic pulmonary
hypertension and to correlate the physiologic and patholog-
ic state of the lung with the degree of expression of Ang-1.
Our results show that Ang-1 is a quantitative marker for pul-
monary hypertension and PVR in the lung. The normal adult
lung does not express Ang-1 at the RNA or protein level. In
contrast, Ang-1 is expressed in the wall of small pulmonary
arteries and arterioles less than 500 µm in diameter in
patients with pulmonary hypertension. The degree of Ang-1
expression at both RNA and protein levels in the lung is
directly proportional to the magnitude of PVR. Thus, in
patients with thromboembolic disease, the Ang-1 gene prod-
uct is a sensitive molecular marker for the severity of pul-
monary hypertension. Although Ang-1 expression was asso-
ciated with the magnitude of preoperative PVR, we cannot
conclude from this study alone whether this change in gene
expression was causal or secondary to the development of
pulmonary hypertension.
Ang-1 is a smooth muscle mitogen and growth factor in
the developing lung.25 This moiety, first isolated in 1996 by
Davis and associates,26 plays a critical role in embryonic
vascular network maturation and remodeling by recruiting
muscle cells to newly formed endothelial tubes. It is a mem-
ber of a 4-gene family (Ang-1, Ang-2, Ang-3, and Ang-4),
each of which is a ligand for endothelium-based tyrosine
kinase membrane receptor TIE2 and its related receptor
TIE1. Ang-2 is a naturally occurring antagonist of Ang-1
and in adult mice is expressed only at sites of vascular
remodeling such as the skin, endometrium, and placenta.27
Its role in the human lung is unknown. Ang-3 and Ang-4
have recently been cloned by sequence homology, and their
physiologic importance and pattern of expression are
unknown.28 Ang-1, in contrast, is responsible for recruiting
and sustaining periendothelial support (muscle) cells in the
maturation and stabilization of the developing neovascula-
ture.29 In addition to its role as a muscular growth factor and
mitogen, Ang-1 has also been shown to up-regulate the
apoptosis inhibitor, survivin, in endothelial cells, through
the serine threonine kinase pathway, Akt, thereby protecting
endothelium from programmed cell death.30 Targeted dis-
ruption of the gene encoding Ang-1 causes embryonic
lethality with severe vascular abnormalities in the develop-
ing mouse.7 Mice rendered null homozygous for Ang-1
have immature cardiac, great vessel, and lung development
with minimal arterial structures forming in these organs.
The lungs of these mutant mice contain venous lake struc-
tures, and vessels lack smooth muscle media investment.
The expression of Ang-1 is thus critical to the development
of a mature pulmonary arterial tree with vessels composed
of intimal, medial, and adventitial layers.
Two important limitations of this study should be recog-
nized. First, because we used the PCR technique to detect
steady-state levels of Ang-1, our study did not distinguish
Figure 6. Localization of Ang-1 protein in lung biopsy specimens (immunohistochemical staining × 200). Immuno-
histochemical analysis with antibody to Ang-1 on lung was obtained from a patient with a PVR of 960 dynes · sec
· cm–5 (A) and a patient with a PVR of 185 dynes · sec · cm–5 (B).
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whether the accumulation of Ang-1 mRNA in the lung
reflected enhanced transcription or enhanced stabilization of
mRNA. Second, because our study examined specimens from
human subjects, it was necessarily limited in scope and time
course. Despite our inability to perform serial biopsies in
individual patients during the progression of pulmonary
hypertension, we found clear evidence that the degree of Ang-
1 expression in the lung at RNA and protein levels parallels
the severity of PVR and degree of pulmonary arteriolar medi-
al thickening. Our results suggest that Ang-1 may be a signal
mechanism for vascular muscle cell hypertrophy and hyper-
plasia in the lung. Further understanding of the effects of
Ang-1 in the pulmonary artery tree may reveal clues for treat-
ing pulmonary hypertension and modulating vascular wall
biology in this organ system.
We thank Angela Ramsey for assistance in the preparation of the
manuscript.
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antibody to Ang-1.
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